Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journal Statistically significant improvement in sleep quality versus sham (p HOUSTON, TX , Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a fourth peer-reviewed article reporting results from clinical research on its 15 mA DIFS™ technology in Alzheimer's disease. The new analysis, published in the Journal of Alzheimer's Disease, found that 15 mA, 40 Hz stimulation delivered with Nexalin's device significantly improved sleep quality in patients with mild Alzheimer's disease compared with sham treatment, with no serious adverse events. The article, "High-intensity transcranial alternating current stimulation improves sleep quality in patients with mild Alzheimer's disease: Findings from the TRANSFORM-AD study" (Qiao et al., Journal of Alzheimer's Disease, 2026; DOI: 10.1177/13872877261492561), was authored by investigators at Xuanwu Hospital , Capital Medical University and the National Center for Neurological Disorders in Beijing, China . It reports a secondary analysis of the TRANSFORM-AD study ( ClinicalTrials.gov NCT03920826), a randomized, double-blind, sham-controlled trial whose earlier results, including improvements in cognitive function and hippocampal theta-gamma coupling, were previously published in Alzheimer's Research & Therapy. The study was funded by the National Key R&D Program of China , and the authors declared no conflicts of interest. Study Design Patients with mild Alzheimer's disease were randomized 1:1 to active stimulation or sham, delivered with Nexalin's Gen-2 SYNC 15 mA device. The active group received 30 one-hour sessions of 40 Hz stimulation at a peak-to-peak amplitude of 15 mA, administered twice daily over 15 consecutive days with electrodes placed on the forehead and bilateral mastoids. The sham group followed an identical protocol with zero current output; active and sham devices were indistinguishable in appearance and sensation, and participants, caregivers, outcome assessors and research nurses remained blinded throughout. Sleep quality, measured by the Pittsburgh Sleep Quality Index (PSQI), was the pre-specified primary outcome of the analysis, with anxiety, depression and quality of life evaluated as exploratory outcomes. Of the 46 randomized participants, 43 (20 active, 23 sham) completed baseline and post-treatment assessments. Key Findings Significant improvement in sleep quality. After adjustment for baseline scores, patients receiving 15 mA stimulation had PSQI scores 2.34 points lower than the sham group at the end of treatment (95% CI, −3.63 to −1.05; p Within-group change. Mean PSQI in the active group fell from 9.65 to 6.35, a reduction of 3.30 points, or approximately 34%, compared with a reduction of 0.52 points in the sham group. Robust across sensitivity analyses. The treatment effect remained significant after additional adjustment for age, sex, education and baseline cognitive scores (−2.56 points; p Favorable safety and tolerability. No serious adverse events were observed in either group. One patient in the active group reported a transient tingling sensation during the first two sessions, and one patient in the sham group reported transient itching at the first session. Exploratory outcomes and limitations. The analysis did not provide conclusive evidence of effects on anxiety, depression or quality of life, which were evaluated as exploratory outcomes. The authors note that participants' low baseline anxiety and depression scores may account for these findings and call for larger, adequately powered trials. They also note that sleep quality was measured with a self-reported questionnaire, that the duration of the effect after treatment is not yet known, and that blinding integrity was not formally assessed. Why Sleep Matters in Alzheimer's Disease According to the authors, approximately 45% of individuals with Alzheimer's disease experience sleep-related problems such as insomnia, sleep fragmentation and excessive daytime sleepiness, and a growing body of evidence supports a bidirectional relationship between sleep disturbance and Alzheimer's pathology. According to the Alzheimer's Association , an estimated 7.4 million Americans age 65 and older are living with Alzheimer's disease in 2026. The authors also propose, as a hypothesis for future research, that improved sleep could be associated with enhanced clearance of pathological proteins such as amyloid-beta, which they note were not measured in this study. The investigators describe the study as the first to evaluate high-intensity stimulation for the management of neuropsychiatric symptoms in Alzheimer's disease, and conclude that the therapy "has potent